Coherus BioSciences logo
Coherus BioSciences CHRS
$ 1.65 -1.5%

Quarterly report 2025-Q3
added 11-06-2025

report update icon

Coherus BioSciences Financial Statements 2011-2026 | CHRS

Annual Financial Statements Coherus BioSciences

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

209 M 524 M 933 M 1.34 B 1.28 B 850 M 583 M 1.17 B 492 M 184 M - - -

Shares

94.2 M 77.6 M 75.4 M 71.4 M 69.7 M 65 M 53.1 M 41.9 M 37.1 M 8.19 M - - -

Historical Prices

2.22 6.75 12.4 18.8 18 13.5 10.1 27.9 13.3 22.4 - - -

Net Income

-238 M -292 M -287 M 132 M 89.8 M -209 M -238 M -127 M -223 M -87.1 M -53.6 M -33 M -

Revenue

257 M 211 M 327 M 476 M 356 M - 1.56 M 190 M 30 M 31.1 M 2.75 M 1.9 M -

Cost of Revenue

159 M 70.1 M 57.6 M 37.7 M 17.1 M - - - - - - - -

Gross Profit

- - - - 339 M - - - 30 M 31.1 M 2.75 M 1.9 M -

Operating Income

-203 M -257 M -264 M 156 M 108 M -204 M -232 M -116 M -219 M -64.7 M -36 M -38.5 M -

Interest Expense

40.5 M 32.5 M 23 M 21.2 M 17.6 M 9.68 M 9.55 M 7.98 M 33 K 3.9 M 5.29 M 1.51 M -

EBITDA

-200 M -253 M -260 M 159 M 111 M -201 M -229 M -113 M -217 M -64 M -35.6 M -38.3 M -

Operating Expenses

- - - - 231 M 204 M 234 M 306 M 249 M 95.8 M 38.7 M 40.4 M -

General and Administrative Expenses

192 M 198 M 170 M 139 M 137 M 94.2 M 71.3 M 51.6 M 36 M 17.6 M 7.46 M 5.53 M -

All numbers in USD currency

Quarterly Income Statement Coherus BioSciences

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

116 M 116 M 116 M 116 M 115 M 115 M 113 M 112 M 97.7 M 87.3 M 79.3 M 78.9 M 77.7 M 77.6 M 77.3 M 76.9 M 79 M 75.6 M 72.8 M 72.5 M 71.6 M 71.1 M 70.7 M 70.4 M 69.9 M 69.5 M 69.1 M 68.3 M 67.8 M 64 M 60.1 M 59.8 M 54.1 M 51.3 M 48.7 M 45.8 M 43.5 M 40.7 M 39.1 M 39 M 38.4 M 37.7 M 33.4 M 33.3 M 4.62 M 4.62 M 4.83 M 4.84 M 4.84 M - - - - - - - - - -

Net Income

-35.5 M 298 M -56.6 M - -10.8 M -12.9 M 103 M - -39.6 M -42.9 M -75.7 M - -86.6 M -50.2 M -96.1 M - -38.5 M -29.9 M -173 M - 27.9 M 59 M 35.6 M 39.2 M 47 M 23.6 M -20 M -62.6 M -58.8 M -43.6 M -44.3 M -49.1 M -59 M -55.3 M -74.8 M -75.9 M 83.9 M -70 M -65.4 M -52.4 M -71.3 M -58.8 M -40.7 M -29.1 M -7.87 M -25 M -25.2 M -14.6 M -21.5 M -8.71 M -8.86 M - - - - - - - -

Revenue

11.6 M 10.3 M 7.6 M - 6.05 M 10.3 M 2.31 M - 74.6 M 58.7 M 32.4 M - 45.4 M 60.2 M 60.1 M - 82.5 M 87.6 M 83 M - 114 M 136 M 116 M 124 M 112 M 83.4 M 37.1 M - - - - - - 1.4 M 161 K 844 K 163 M 14.1 M 12.4 M 10.2 M 7.17 M 6.87 M 5.81 M 6.49 M 16.1 M 4.96 M 3.6 M 1.23 M 506 K 507 K 506 K - - - - - - - -

Cost of Revenue

3.72 M 3.4 M 2.65 M - 2.73 M 1.81 M 1.44 M - 32.7 M 24.8 M 16.9 M - 35.2 M 11.3 M 9.37 M - 21.3 M 16.7 M 7.51 M - 9 M 10.1 M 6.86 M - - 601 K 2.22 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - 116 M 105 M 82.8 M 34.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-44.3 M -45.5 M -45.4 M - -46.9 M -39.6 M -67.8 M - -32 M -34.5 M -67.7 M - -80.4 M -44 M -80.9 M - -32.8 M -24.2 M -167 M - 33.7 M 65.3 M 40.9 M - 51.8 M 27.5 M -16.6 M - -57 M -44.9 M -42 M - -56.6 M -56.6 M -72.4 M - 84.6 M -62.7 M -64.4 M - -71.2 M -58.9 M -36.7 M - -6.42 M -17.9 M -13.8 M - -6.78 M - - - - - - - - - -

Interest Expense

2.32 M 2.28 M 2.15 M - 2.83 M 4.06 M 3.12 M - 10.3 M 9.94 M 9.71 M - 7.54 M 6.58 M 8.97 M - 5.77 M 5.75 M 5.65 M - 5.66 M 5.41 M 4.43 M - 4.47 M 4.43 M 4.22 M - 2.42 M 2.42 M 2.41 M - 2.39 M 2.38 M 2.38 M - 2.42 M 2.35 M 837 K - 33 K -139 K -4.09 M - 1 K 1.16 M 2.74 M - 1.99 M - - - - - - - - - -

EBITDA

-44 M -45.2 M -45 M - -46.5 M -39.1 M -67.2 M - -31.2 M -33.7 M -66.8 M - -79.5 M -43.1 M -80.2 M - -31.9 M -23.3 M -167 M - 34.4 M 66 M 41.5 M - 52.6 M 28.2 M -15.9 M - -56.2 M -44 M -41.1 M - -55.8 M -55.8 M -71.6 M - 85.4 M -62 M -63.6 M - -70.6 M -58.5 M -36.5 M - -6.23 M -17.8 M -13.6 M - -6.68 M - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - 79.8 M 70.4 M 75.3 M 78.8 M 59.8 M 55.9 M 53.7 M 60.5 M 57 M 44.9 M 42 M 46.5 M 56.6 M 58 M 72.6 M 74.3 M 78.2 M 76.8 M 76.7 M 62.4 M 78.4 M 65.8 M 42.6 M 33.1 M 22.5 M 22.9 M 17.4 M 11.7 M 7.29 M 9.79 M 9.94 M - - - - - - - -

General and Administrative Expenses

24.9 M 26 M 26 M - 28.1 M 27.5 M 40.2 M - 48.2 M 45.1 M 49.2 M - 44.8 M 51.3 M 48.8 M - 39.9 M 40.3 M 39.4 M - 32 M 34.1 M 35.4 M - 31.8 M 36.5 M 32.7 M - 25.4 M 18.4 M 16.6 M - 14 M 23.5 M 18.8 M - 13.6 M 11.3 M 11.4 M - 10.2 M 8.82 M 6.09 M - 3.98 M 3.98 M 3.42 M - 2.36 M - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Coherus BioSciences CHRS
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Coherus BioSciences plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alector Alector
ALEC
$ 2.19 -9.77 % $ 226 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Cabaletta Bio Cabaletta Bio
CABA
$ 3.34 0.45 % $ 3.9 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Codexis Codexis
CDXS
$ 1.02 1.49 % $ 74.9 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.74 3.6 % $ 1.12 B canadaCanada
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.6 1.37 % $ 480 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.87 -0.39 % $ 116 M franceFrance
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 3.23 2.22 % $ 1.23 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 41.75 0.19 % $ 1.32 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 36.14 1.23 % $ 3.75 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 13.98 1.27 % $ 5.7 B irlandaIrlanda
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 23.77 2.99 % $ 2.91 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.41 -1.87 % $ 36.4 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.94 0.01 % $ 130 M usaUSA
Curis Curis
CRIS
$ 1.1 -3.51 % $ 6.94 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
CorMedix CorMedix
CRMD
$ 7.16 0.42 % $ 364 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Champions Oncology Champions Oncology
CSBR
$ 6.14 3.89 % $ 83.9 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.72 -2.34 % $ 4.84 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Altimmune Altimmune
ALT
$ 4.21 -2.32 % $ 299 M usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 3.88 -8.92 % $ 247 M usaUSA